Intermediate-risk acute myeloid leukemia therapy: current and future.

@article{Doehner2014IntermediateriskAM,
  title={Intermediate-risk acute myeloid leukemia therapy: current and future.},
  author={Konstanze Doehner and Peter Paschka},
  journal={Hematology. American Society of Hematology. Education Program},
  year={2014},
  volume={2014 1},
  pages={34-43}
}
In recent years, research in molecular genetics has been instrumental in deciphering the molecular heterogeneity of acute myeloid leukemia (AML), in particular the subset of patients with "intermediate-risk" cytogenetics. However, at present, only the markers NPM1, CEBPA, and FLT3 have entered clinical practice. Treatment of intermediate-risk AML patients eligible for intensive therapy has not changed substantially. The "3 + 7" induction therapy still represents the standard of care. The… CONTINUE READING